Three ‘E’ challenges for siRNA drug development
Authors:
- 9 November 2023
- journal article
- research article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 30 (1) , 13-24
Abstract
No abstract availableKeywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- National Key Research and Development Program of China (2021YFA1201000, 2021YFC2302400, 2021YFE0106900)
- Fundamental Research Funds for the Central Universities (2022CX01013)
- National Natural Science Foundation of China (32171394)
- Beijing Nova Program (20220484207)
- Beijing Institute of Technology
This publication has 82 references indexed in Scilit:
- Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD TreatmentMolecular Therapy Nucleic Acids, 2012
- Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeuticsNature Nanotechnology, 2011
- RNA interference in the clinic: challenges and future directionsNature Reviews Cancer, 2010
- Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAsRNA, 2009
- The Effect of Chemical Modification and Nanoparticle Formulation on Stability and Biodistribution of siRNA in MiceMolecular Therapy, 2009
- Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion proteinNature Biotechnology, 2009
- Mechanisms and optimization of in vivo delivery of lipophilic siRNAsNature Biotechnology, 2007
- 2′-O-methyl-modified RNAs Act as TLR7 AntagonistsMolecular Therapy, 2007
- Cell type–specific delivery of siRNAs with aptamer-siRNA chimerasNature Biotechnology, 2006
- Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptorsNature Biotechnology, 2005